Issue Date: January 24, 2011
Merck Serono, Domain Join For Parkinson's
Merck Serono and Domain Therapeutics will jointly develop allosteric modulators of mGluR4, a glutamate receptor that is implicated in Parkinson’s and other neurodegenerative diseases. Domain initially scores $2.7 million in research funding and an up-front fee, and it could bring in up to $175 million in milestones as the first two products move through clinical trials. Domain will hand over optimized compounds discovered in its internally developed chemical series.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society